GT Biopharma, Inc. (NASDAQ:GTBP – Get Free Report) was the recipient of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 19,300 shares, a growth of 14.9% from the July 31st total of 16,800 shares. Approximately 0.9% of the company’s shares are short sold. Based on an average trading volume of 42,500 shares, the short-interest ratio is currently 0.5 days.
GT Biopharma Trading Down 1.5 %
GTBP opened at $2.15 on Friday. The business’s 50 day moving average price is $2.56 and its 200 day moving average price is $3.42. GT Biopharma has a one year low of $2.07 and a one year high of $10.66.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in GT Biopharma stock. DekaBank Deutsche Girozentrale acquired a new position in shares of GT Biopharma, Inc. (NASDAQ:GTBP – Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,093,645 shares of the company’s stock, valued at approximately $47,449,000. DekaBank Deutsche Girozentrale owned 77.02% of GT Biopharma at the end of the most recent quarter. 8.15% of the stock is owned by institutional investors.
About GT Biopharma
GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.
Recommended Stories
- Five stocks we like better than GT Biopharma
- Short Selling: How to Short a Stock
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- There Are Different Types of Stock To Invest In
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.